Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Dec 12;12(12):CD001368.
doi: 10.1002/14651858.CD001368.pub4.

Naftidrofuryl for intermittent claudication

Tine L M de Backer  1 , Robert Vander Stichele, Philippe Lehert, Luc Van Bortel
Affiliations
Meta-Analysis

Naftidrofuryl for intermittent claudication

Tine L M de Backer et al. Cochrane Database Syst Rev. .

Abstract

Background: Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organisation class CO4A) is controversial.

Objectives: To evaluate evidence on the efficacy and safety of oral naftidrofuryl (ATC CO4 21) versus placebo on the pain-free walking distance (PFWD) of people with IC by using a meta-analysis based on individual patient data (IPD).

Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched October 2012) and CENTRAL (2012, Issue 9).For the original review the authors handsearched the European Journal of Vascular and Endovascular Surgery (1984 to 1994) and checked relevant bibliographies. They contacted the registration holder of naftidrofuryl and the authors of identified trials for any unpublished data.

Selection criteria: We included only randomized controlled trials (RCTs) with low or moderate risk of bias for which the IPD were available.

Data collection and analysis: We collected data from the electronic data file or from the case report form and checked the data by a statistical quality control procedure. All randomized patients were analyzed following the intention-to-treat (ITT) principle. The geometric mean of the relative improvement in PFWD was calculated for both treatment groups in all identified studies.The effect of the drug was assessed compared with placebo on final walking distance (WDf) using multilevel and random-effect models and adjusting for baseline walking distance (WD0). For the responder analysis, therapeutic success was defined as an improvement of walking distance of at least 50%.

Main results: We included seven studies in the IPD (n = 1266 patients). One of these studies (n = 183) was only used in the sensitivity analysis so that the main analysis included 1083 patients. The ratio of the relative improvement in PFWD (naftidrofuryl compared with placebo) was 1.37 (95% confidence interval (CI) 1.27 to 1.49, P < 0.001). The absolute difference in responder rate, or proportion successfully treated, was 22.3% (95% CI 17.1% to 27.6%). The calculated number needed to treat was 4.5 (95% CI 3.6 to 5.8).

Authors' conclusions: Oral naftidrofuryl has a statistically significant and clinically meaningful, although moderate, effect of improving walking distance in the six months after initiation of therapy for people with intermittent claudication. Access by researchers to data from RCTs that are suitable for IPD analysis should be possible through repositories of data from pharmacological trials. Regular formal appraisal of the balance of risk and benefit is needed for older pharmaceutical products.

PubMed Disclaimer

Conflict of interest statement

Tine de Backer, Robert Vander Stichele and Luc Van Bortel have no conflict of interests. Philippe Lehert has performed statistical consultancy for a number of pharmaceutical companies, including Merck which holds the marketing authorization for naftidrofuryl.

Figures

1
1
Mean change and baseline handicap
1.1
1.1. Analysis
Comparison 1 Naftidrofuryl (NFD) versus placebo: responder rate, Outcome 1 Responder rate naftidrofuryl versus placebo.
2.1
2.1. Analysis
Comparison 2 Naftidrofuryl (Nfd) versus placebo: WDf‐WD0. Mean gain naftidrofuryl over placebo, Outcome 1 Mean gain in meters PFWD of naftidrofuryl over placebo.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Adhoute 1986 {published and unpublished data}
    1. Adhoute G, Bacourt F, Barral M, Cardon JM, Chevalier JM, Cuny A, et al. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 1986;37:160‐7. - PubMed
Adhoute 1990 {published and unpublished data}
    1. Adhoute G, Andreassian B, Boccalon H, Cloarec M, Maria G, Lefebvre O, et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: Results after 6 months of a controlled, multicenter study. Journal of Cardiovascular Pharmacology 1990;16(Suppl):75‐80. - PubMed
Boccalon 2001 {published and unpublished data}
    1. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Annales de Cardiologie et d Angeiologie 2001;50(3):175‐82. - PubMed
Kieffer 2001 {published and unpublished data}
    1. Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication International. Angiology 2001;20(1):58‐65. - PubMed
Kriessman 1988 {published and unpublished data}
    1. Kriessman A, Neiss A. Clinical effectiveness of naftidrofuryl in intermittent claudication [Naftidrofuryl bei der peripher arteriellen verschlusskrankheit]. VASA 1988;17(Suppl 24):27‐32. - PubMed
Maass 1984 {published and unpublished data}
    1. Maass U, Amberger H‐G, Bohme H, Diehm C, Dimroth H, Heidrich H, et al. Naftidrofuryl in arterial occlusive disease [Naftidrofuryl bei arterieller Verschlusskrankheit. Kontrollierte multizentrische Doppelblindstudie mit oraler Applikation]. Deutsche Medizinische Wochenschrift 1984;109:745‐50. - PubMed
Moody 1994 {published and unpublished data}
    1. Moody AP, Al‐Khaffaf HS, Lehert P, Harris PL, Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. Journal of Cardiovascular Pharmacology 1994;23(Suppl 3):44‐7. - PubMed

References to studies excluded from this review

Clyne 1980 {published and unpublished data}
    1. Clyne CAC, Galland RB, Fox MJ, Gustave R, Jantet GH, Jamieson CW. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. British Journal of Surgery 1980;67:347‐8. - PubMed
Karnik 1988 {published and unpublished data}
    1. Karnik R, Valentin A, Stollberger C, Slany J. Effects of naftidrofuryl in patients with intermittent claudication. Angiology 1988;39(3):234‐40. - PubMed
Pohle 1979 {published data only}
    1. Pohle W, Hirche H, Barmeyer J, Schumichen C, Hoffman G. A double‐blind trial of naftidrofuryl hydrogen oxalate in patients suffering from occlusive peripheral arterial disease. Medizinische Welt 1979;30(7):269‐72. - PubMed
Ruckley 1978 {published and unpublished data}
    1. Ruckley CV, Callam MJ, Ferrington CM, Prescott RJ. Naftidrofuryl for intermittent claudication: a double‐blind controlled trial. British Medical Journal 1978;1:622. - PMC - PubMed

Additional references

Anderson 1957
    1. Anderson TW. Maximum likelihood estimates for a multivariate normal distribution when some observations are missing. Journal of the American Statistical Association 1957;52:200‐3.
Aung 2007
    1. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid‐lowering for peripheral arterial disease of the lower limb. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD000123.pub2] - DOI - PMC - PubMed
Burns 2003
    1. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ 2003;326(7389):584‐8. - PMC - PubMed
Cameron 1988
    1. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965‐1985. British Journal of Clinical Pharmacology 1988;26(5):569‐76. - PMC - PubMed
Carman 2000
    1. Carman TL, Fernandez BB Jr. A primary care approach to the patient with claudication. American Family Physician 2000;61(4):1027‐32,1034. - PubMed
CLIPS 2007
    1. Critical Leg Ischaemia Prevention Study (CLIPS) Group, Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double‐blind trial. Journal of Internal Medicine 2007;261(3):276‐84. - PubMed
Coffman 1979
    1. Coffman JD. Intermittent claudication and rest pain: physiologic concepts and therapeutic approaches. Progress in Cardiovascular Diseases 1979;22(1):53‐72. - PubMed
Cohen 1988
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2nd Edition. New Jersey: Lawrence Erlbaum, 1988.
CPMP Working Party
    1. CPMP Working Party. Clinical investigations of medicinal products in the treatment of chronic peripheral arterial disease. Note for guidance EMEA Status as of October 2002. http://www.emea.europa.eu/pdfs/human/ewp/071498en.pdf (accessed 23 May 2007).
Criqui 1985
    1. Criqui MH, Fronek A, Barrett‐Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71(3):510‐5. - PubMed
D'Hooge 2001
    1. D'Hooge D, Lehert P, Clement DL. Naftidrofuryl in quality of life (NIQOL). A Belgian study. International Angiology 2001;20(4):288‐94. - PubMed
De Backer 2000
    1. Backer TL, Vander Stichele RH, Bogaert MG. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD000988.pub2] - DOI - PubMed
De Backer 2000b
    1. Backer TL, Vander Stichele RH, Warie HH, Bogaert MG. Oral vasoactive medication in intermittent claudication: utile or futile?. European Journal of Clinical Pharmacology 2000;56(3):199‐206. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Diehm 2004
    1. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co‐morbidity in 6880 primary care patients: cross‐sectional study. Atherosclerosis 2004;172(1):95‐105. - PubMed
Dormandy 2000
    1. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAltlantic Inter‐Society Consensus (TASC). Journal of Vascular Surgery 2000;31(Pt 2):1‐296. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
EMEA
    1. The European Agency for the Evaluation of Medicinal Products (EMEA). ICH Topic E 6. Guideline for Good Clinical Practice. http://www.emea.eu.int/pdfs/human/ich/013595en.pdf (accessed 28 August 2004).
Fontaine 1954
    1. Fontaine VR, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstorungen]. Helvetica Chirurgica Acta 1954;21:499‐533. - PubMed
Fowkes 1991
    1. Fowkes FG, Housley E, Cawood EH, MacIntyre CA, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384‐92. - PubMed
Gehr 2006
    1. Gehr BT, Weiss C, Porzsolt F. The fading of reported effectiveness. A meta‐analysis of randomized controlled trials. BMC Medical Research Methodology 2006;6(25):1‐12. - PMC - PubMed
Girolami 1999
    1. Girolami B, Bernardi E, Prins MH, Cate JW, Hettiarachchi R, Prandoni P, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta‐analysis. Archives of Internal Medicine 1999;159(4):337‐45. - PubMed
Goldsmith 2005
    1. Goldsmith DR, Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs and Aging 2005;22(11):967‐77. - PubMed
Hiatt 1995
    1. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91(5):1472‐9. - PubMed
Higgins 2001
    1. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta‐analysis of continuous outcome data from individual patients. Statistics in Medicine 2001;20:2219‐41. - PubMed
Hood 1996
    1. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta‐analysis of randomized controlled trials. Canadian Medical Association Journal 1996;155(8):1053‐9. - PMC - PubMed
Hooi 2004
    1. Hooi JD, Kester AD, Stoffers HE, Rinkens PE, Knottnerus JA, Ree JW. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7‐year follow‐up study. Journal of Clinical Epidemiology 2004;57(3):294‐300. - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. - PubMed
Kleijnen 1998
    1. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 1. [DOI: 10.1002/14651858.CD000987] - DOI - PMC - PubMed
Lehert 1990
    1. Lehert P, Riphagen FE, Gamand S. The effect of naftidrofuryl on intermittent claudication: a meta‐analysis. Journal of Cardiovascular Pharmacology 1990;16(Suppl 3):81‐6. - PubMed
Leng 2000
    1. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD000990] - DOI - PubMed
Li 2003
    1. Li XY, Wang J, He Y, Fan L. The relation between peripheral arterial occlusive disease and cardiovascular diseases in elderly population: a cross‐section study in Wanshoulu area,Beijing. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2003;83(21):1847‐51. - PubMed
Mil‐STD 105D
    1. Defense Standardization Program. Military Standards 105D ‐ Quality on Data Entry process. http://www.dsp.dla.mil (accessed 27 August 2004).
Moher 2000
    1. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a meta‐analysis of randomised trials. Drugs 2000;59(5):1057‐70. - PubMed
Mohler 2003
    1. Mohler ER 3rd. Peripheral arterial disease: identification and implications. Archives of Internal Medicine 2003;163(19):2306‐14. - PubMed
Reiter 2003
    1. Reiter M, Bucek RA, Stümpflen A, Minar E. Prostanoids for intermittent claudication. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD000986.pub2] - DOI - PubMed
Robless 2007
    1. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD003748.pub2] - DOI - PubMed
SIGN 2006
    1. Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease. A national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN) 2006;89:1‐41.
Sommerfield 2007
    1. Sommerfield T, Price J, Hiatt WR. Omega‐3 fatty acids for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003833.pub3] - DOI - PubMed
TASC II 2007
    1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASCII Working Group. Inter‐society consensus for the management of peripheral arterial disease (TASC II). European Journal of Vascular and Endovascular Surgery 2007;33 Suppl 1:1‐75. - PubMed
Turner 2000
    1. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine 2000;19(24):3417‐32. - PubMed
Verhaege 1998
    1. Verhaeghe R. Epidemiology and prognosis of peripheral obliterative arteriopathy. Drugs 1998;56(Suppl 3):1‐10. - PubMed
Walker 1995
    1. Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387‐94. - PubMed
WHO
    1. World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). http://www.who.int/classifications/atcddd/en/ (accessed July 2007).

References to other published versions of this review

de Backer 2008
    1. Backer TLM, Vander Stichele R, Lehert P, Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD001368.pub3] - DOI - PubMed

Publication types

MeSH terms